{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:06:40Z","timestamp":1793153200266,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"American Cancer Society The American Cancer Society","award":["MRSG-13-077-01"],"award-info":[{"award-number":["MRSG-13-077-01"]}]},{"name":"South Carolina SmartState Program"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["1R01CA165609-01A1"],"award-info":[{"award-number":["1R01CA165609-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["3R01CA165609-03S1"],"award-info":[{"award-number":["3R01CA165609-03S1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.leukres.2016.03.004","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T18:25:24Z","timestamp":1458152724000},"page":"61-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry"],"prefix":"10.1016","volume":"44","author":[{"given":"Jametta S.","family":"Magwood-Golston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.03.004_bib0005","first-page":"149","article-title":"Systematic approach to pharmacovigilance beyond the limits: the southern network on adverse reactions (SONAR) projects","volume":"3","author":"Lu","year":"2014","journal-title":"Adv. Pharmacoepidemiol. Drug Saf."},{"issue":"July (2)","key":"10.1016\/j.leukres.2016.03.004_bib0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.03.004_bib0015","series-title":"Pfizer Voluntarily Withdraws Cancer Treatment from United States Market","year":"2010"},{"issue":"5","key":"10.1016\/j.leukres.2016.03.004_bib0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2016.03.004_bib0025","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12185-013-1275-2","article-title":"Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice","volume":"97","author":"Tallman","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2016.03.004_bib0030","first-page":"599","article-title":"A prospective observational study of gemtuzumab ozogamicin in routine clinical practice","volume":"31","author":"Tallman","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.03.004_bib0035","first-page":"3258","article-title":"Prospective observational study of Mylotarg in usual care. An update","volume":"102","author":"Tallman","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.03.004_bib0040","first-page":"749a","article-title":"Gemtuzumab ozagomicin (GO(Mylotarg)) associated sinusoidal obstructive syndrome (SOS) occurs at higher rates in off-Label clinical settings: an overview of cases reported to the FDA and in the medical literature","volume":"102","author":"Chacko","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.03.004_bib0045","unstructured":"Pharmaceutical and Medical Devices Safety Information. February 2011. (277), https:\/\/www.pmda.go.jp\/files\/000153067.pdf (2011) (accessed 02.05.16)."},{"key":"10.1016\/j.leukres.2016.03.004_bib0050","series-title":"European Medicines Agency. January 24, 2008. EMEA\/CHMP\/51302008","author":"Refusal assessment report for Mylotarg","year":"2008"},{"key":"10.1016\/j.leukres.2016.03.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T04:51:11Z","timestamp":1536900671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":11,"alternative-id":["S0145212616300315"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.03.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}